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Summary
Background- The aim of this study was to assess the pharma-
cology, toxicity and activity of high-dose ifosfamide/mesna
± GM-CSF administered by a five-day continuous infusion at
a total ifosfamide dose of 12-18 g/m2 in adult patients with
advanced sarcomas.
Patients and methods: Between January 1991 and October
1992 32 patients with advanced or metastatic sarcoma were
entered the study. Twenty-seven patients were pretreated in-
cluding twenty-three with prior ifosfamide at less than 8 g/m2
total dose/cycle. In 25 patients (27 cycles) extensive pharma-
cokinetic analyses were performed.
Results: The area under the plasma concentration-time
curve (AUC) for ifosfamide increased linearly with dose while
the AUC's of the metabolites measured in plasma by thin-layer
chromatography did not increase with dose, particularly that
of the active metabolite isophosphoramide mustard. Further-
more the AUC of the inactive carboxymetabolite did not
increase with dose. Interpatient variability of pharmacokinetic
parameters was high. Dose-limiting toxicity was myelosup-
pression at 18 g/m2 total dose with grade 4 neutropenia in five
of six patients and grade 4 thrombocytopenia in four of six
patients. Therefore the maximum tolerated dose was con-
sidered to be 18 g/m2 total dose. There was one CR and eleven
PR in twenty-nine evaluable patients (overall response rate
41%).
Conclusion: Both the activation and inactivation pathways
of ifosfamide are non-linear and saturable at high-doses
although the pharmacokinetics of the parent drug itself are
dose linear. Ifosfamide doses greater than 14-16 g/m2 per
cycle appear to result in a relative decrease of the active
metabolite isophosphoramide mustard. These data suggest a
dose-dependent saturation or even inhibition of ifosfamide
metabolism by increasing high dose ifosfamide and suggest
the need for further metabolic studies.
Key words: high-dose ifosfamide, metabolism, pharmacology,
sarcomas
Introduction
The alkylating agent ifosfamide (IFO) in conjunction
with the uroprotective agent mesna (2-mercaptoethane-
sulfonate sodium) has demonstrated clinical activity
against a wide range of tumor types [1]. For treatment
of soft tissue sarcoma only the anthracyclines, DTIC
and the oxazaphosphorine IFO have consistently shown
response rates of >20% in non-pretreated sarcoma
patients [2-4]. Combination chemotherapy seems to
improve the response rate, but it is not certain that this
translates into an overall survival benefit [5-7]. Serious
side effects of IFO include myelosuppression, nausea
and vomiting, alopecia, uro- and CNS-toxicity [8].
Preliminary results of high dose IFO/mesna (IFO-
dose #: 10 g/m2 per cycle) in sarcoma patients with
different subtypes indicate therapeutic efficacy even in
pretreated patients [9-14]. Continuous IFO/mesna ap-
plication has been shown to be less toxic as compared to
fractionated i.v. infusions and preclinical and clinical
data are consistent with a higher therapeutic index for
the continuous infusion schedule over several days
[15-18]. For this reason we chose a schedule with con-
tinuous IFO when this trial commenced. Subsequently,
a report suggested that repetitive 2-hour infusions every
12 hours to a total dose of 14 g/m2 may be more effective
at inducing clinical response than the same total dose
delivered by continuous infusion over three days [14].
In contrast, using a conventional dose of IFO (6 to 9
g/m2), there was no demonstrable difference between a
bolus IFO-administration and a continuous infusion
schedule of the same total dose [19].
Ifosfamide is a prodrug which is metabolised in vivo
to produce a variety of active and potentially toxic
metabolites (Figure 1). The bioactivation is mediated by
a cytochrome p450 enzyme (CYP3A4) and results in
hydroxylation at the carbon-4 position of the oxazaphos-
phorine ring. This 4-hydroxy-ifosfamide (4-OH-IFO) is
unstable and exists in equilibrium with its tautomeric
form aldoifosfamide (aldo-IFO). Aldo-IFO decomposes
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Figure 1. Pathways of metabolism of lfosfamide.
spontaneously to form the alkylating agent isophos-
phoramide mustard (IPM) and acrolein. By its alkylat-
ing ability IPM is assumed to be the active metabolite of
IFO. The by-product acrolein is believed to be respon-
sible for the urotoxic effects of IFO [20]. Alternatively
aldo-IFO can be oxidised by an aldehyde dehydrogenase
enzyme (ALDH1) to carboxy-IFO (CX) which is an in-
active metabolite. Approximately half of the dose of IFO
undergoes oxidative N-dealkylation to produce either
2- or 3-dechloroethyl-IFO (2-DCI, 3-DCI respectively).
An equimolar quantity of chloroacetaldehyde (CA) is
formed in each of these reactions and this toxic metab-
olite has been implicated in the neurotoxicity which may
accompany IFO-therapy [21] and may furthermore be
associated with nephrotoxicity. Oxidation of 4-hydroxy-
ifosfamide results in another inactive metabolite which
is 4-keto-IFO (KETO).
Pharmacokinetic and metabolism data are scarce for
patients treated with high-dose IFO [22, 23]. Since IFO
is a prodrug and needs to be activated in vivo, there may
be saturation of metabolism which would preclude very
high dose treatment with this agent. A similar saturation
phenomenon has been noted with cyclophosphamide
[24, 25]. We therefore examined the pharmacokinetics
of IFO and its metabolites in patients with high-dose
IFO/mesna, in combination with hematopoietic growth
factors, where indicated, in this dose escalation study.
Pharmacokinetic data for high-dose mesna and endo-
genous sulphydrils have been published elsewhere [26].
Patients and methods
Patients
Patients with a histologically confirmed diagnosis of inoperable soft
tissue, osteo- or chondrosarcoma with measurable disease were eligible
for study. Pretreatment with chemotherapy was allowed. Prior treat-
ment with IFO was limited to less than 8 g/m2 per cycle. Furthermore
a WHO performance status < 2 and age < 70 years was mandatory. A
creatinine-clearance > 6 0 ml/min. liver enzymes ^ 2 x normal values,
leukocytes 5:3.5 x 1O9/I, thrombocytes > 100 x 1O9/1 and hemoglobin
^ 10 g/dl were other inclusion criteria. The patients had to give
informed consent and the study was accepted by the local ethical
committees
Treatment plan
In order to define the maximum tolerated dose (MTD) of ifosfamide
as a continuous infusion over five days the treatment design was to
escalate the daily dose from level 1 to level 3 as described below At
each level the inclusion of four patients was planned. If a granulocyte-
nadir of <0.1 x 109/l with an infectious episode (requiring i.v anti-
biotics) and/or a thrombocyte-nadir of < 50 x 109/l or any other
important non-hematological toxicities (excluding alopecia or nausea
and vomiting) such as CNS toxicity grade 3 or higher occurred in the
first course of two patients of a particular dose level, this level was
considered as the maximal tolerated dose (MTD). As we did not reach
the MTD in any patient in level 3 and observed encouraging responses
we decided after patient 20 (the 12th patient on level 3) to escalate the
dose to a further level 4 for the following patients. The first patient at
level I had a partial remission after seven cycles and received a second-
line treatment at level 4 later on when his tumor became progressive
again. MTD was achieved at dose level 4. Therefore, the recommended
dose was considered to be 16 g/m2 of IFO per cycle (level 3) and seven
additional patients were treated at this level (Table 1).
IFO was given in 2 liters of normal saline or dextrose 5% daily as a
continuous i.v. infusion. Mesna was added to IFO in the same infusion
bag. On day 6 mesna was administered at the same daily dose for an
additional 24 hours. An antiemetic agent was given and bicarbonate
was replaced at the discretion of the treating physician. Because grade
4 granulocytopenia was repeatedly encountered at level I, all subse-
quent patients starting at level 2 received GM-CSF (leucomax) at a
dose of 5 ug/kg sc. once daily starting on day 7 until day 16 (total of
10 doses). If granulocyles had not reached 5=0.5 x 109 on day 16.
GM-CSF application was continued until day 20. The next chemo-
therapy cycle was started on day 22 if the following criteria were met:
leukocytes > 3.5 x 1O9/1, thrombocytes > 100 x 1O9/1, Cr-clearance
5 60 ml/min. Otherwise the cycle was postponed by one week or if the
criteria could still not be met. the patient was taken off treatment.
Toxicity and response assessment
Pretreatment evaluation included standard history, physical examina-
tion, a complete blood cell count, electrolytes and biochemical assess-
ment of liver and kidney function as well as urinalysis. History,
physical examination and the laboratory tests were repeated before
each cycle. A chest X-ray and tumor measurement of all evaluable
lesions by conventional X-ray or computed tomographic scan at base-
line were mandatory. Tumor imaging and chest X-ray were repeated
every second cycle. Complete blood cell count with differential count
was obtained every week. A complete laboratory and radiological
work up was performed after the last chemotherapy cycle. Toxicity
was evaluated according to WHO criteria, except for neurotoxicity
which was measured by M.D. Anderson score [27].
Complete response (CR) was defined as the disappearance of all
clinical evidence of tumor Pathologic complete response (pCR) was
defined as no viable tumor in the resected specimen that represented
the residual radiological abnormality1. Partial response (PR) was defined
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Table I. Patient characteristics and treatment results.
Dose No. Sex Age Primary Grading Stage Initial WHO No. ofpre-
level tumor (NCI) (AJCC) performance treatments
type
Pretreat- No. of Response Resp. Survival
ments cyles duration (weeks)
incl. ifos (weeks)
1 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
r-l
22
23
24
25
26
27
28
29
30
31
32
m
f
m
m
m
m
m
m
m
f
f
f
m
f
m
m
m
f
f
f
m
m
f
f
m
m
f
m
f
f
m
f
48
40
33
65
37
51
46
62
52
22
39
51
27
71
40
22
46
42
44
54
36
61
65
53
52
47
24
23
64
48
63
46
STS*
CHS
CHS
OS
STS
STS
CHS
STS
STS
STS
STS*
STS*
STS*
STS
OS
NB
STS
STS*
STS*
STS
CHS
STS
STS*
STS*
STS*
OS
OS
STS
STS
STS
STS*
STS
3
3
2
-
3
3
3
3
3
3
3
3
3
3
-
3
3
2
2
2
2
3
3
2
3
_
3
2
3
3
4B
4B
4B
4B
4B
4B
4B
3B
4B
4B
4A
4B
4B
4A
4B
3B
3B
4B
4A
4B
4B
4A
4B
4B
4B
4B
4B
4B
4A
4B
4B
4B
1
1
2
2
0
1
0
0
0
0
0
0
0
1
1
1
2
0
0
2
2
0
0
1
0
1
1
1
1
1
1
9
6
7
2
9
6
5
1
2
4
3
2
4
4
1
3
5
2
2
1
2
1
1
2
1
2
4
4
2
4
2
1
PR
NC
PR
NC
PR
PR
NC
ne
PR
PR
CR
PD
NC
PR
PD
NC
PR
PD
NC
PD
PD
PD
uk
PR
PD
NC
PR
NC
NC1
PR
PD
uk
44
_
26
-
84
52
_
-
13
48
31
_
-
40
-
-
31
-
-
_
_
-
24
-
_
77
_
_
25
-
129
40
57
30
161
73
76
2
13
67
40
37
61
47
6
77
39
37
83
35
46
35
59
41
17
144*
134*
55
29
73
36
II
Abbreviations: STS - soft tissue sarcoma: STS* - leiomyosarcoma, OS - osteosarcoma; CHS - chondrosarcoma; NB - neuroblastoma; ne
not evaluable; NC' - PR but no confirmatory X-ray: uk - unknown; * * - lost for follow up. week patient last seen.
as a ^ 5 0 % reduction in the sum of the products of the biperpendicular
diameters of measurable lesions, without the appearance of new
lesions for at least three weeks. Minor response (MR) was defined as a
decrease in tumor size between 25% and 49%. Stable disease (SD) was
defined as a less than 25% change in the dimensions of the tumor, and
progressive disease (PD) was defined as a ^ 25% increase in the sum of
the perpendicular diameters and/or appearance of new lesions. Sur-
vival was measured in weeks from the first day of treatment until the
date of death. Response duration in patients with complete or partial
response was calculated as the time from the first day of treatment until
the date of diagnosis of relapse.
Pharmacokinetics and metabolite analyses
lfosfamide and its metabolites were obtained from Asta Medica, Frank-
furt. Germany. Cyclophosphamide (internal standard) and 4-nitro-
benzylpyridine (NBP) were purchased from Sigma All other reagents
were of appropriate analytical grade.
During the first cycle blood samples were collected immediately
before and at 12, 24, 36. 48, 72, 96, 120, 132 and 144 hours after the
start of treatment. Blood was heparinised and plasma was separated
and frozen immediately at -20 "C prior to analysis. Urine was col-
lected at 24-hour intervals throughout the infusion and for 24 hours
after. The volume of each urine sample was measured and an aliquot
was frozen at -20 °C for subsequent analysis
Concentrations of lfosfamide (IFO). isophosphoramide mustard
(IPM), carboxyifosfamide (CX), 2- and 3-dechloroethylifosfamide
(2- and 3-DCI) and 4-ketoifosfamide (KETO) were determined in
urine and plasma, using gas chromatography (GC) for IFO [28] and a
quantitative thin-layer chromatography-photography densitometry
technique (TLC) for the metabolites [29].
Exposure of each patient to ifosfamide and each of its metabolites
was expressed as the area under the plasma concentration-time curve
(AUC) for that species. This was calculated by the trapezoidal method.
When comparing AUCs for different metabolites at different doses.
AUC divided by dose was used as a measure of comparison. The AUC
for IFO was used to calculate clearance (Cl). Due to the sparcity of
lfosfamide data beyond the end of the infusion and the induction of
its own metabolism, it was not possible to calculate other pharma-
cokinetic parameters such as half-life and volume of distribution.
Recoveries of parent drug and metabolites in urine were expressed as
a percentage of the administered dose. Both AUC and percents of dose
were corrected for molecular weight.
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Statistics
Due to small sample size, patient characteristics, response and toxicity
were presented by descriptive statistic only. Survival probabilities were
estimated by Kaplan-Meier method. Spearman rank correlation was
used to determine the relationships between drug and metabolite
pharmacokinetics and dose. The Mann-Whitney U-test was used to
compare data from different dose levels.
Results
Patient characteristics
Thirty-one patients with advanced or metastatic sarco-
ma and one patient with a neuroblastoma were entered
into this Swiss national study between January 1991 and
October 1992. The latter was included even though this
tumor does not fulfil the histological criteria of a sarco-
ma because this type of tumor also responds well to
ifosfamide and because the main aim of the study was
to examine the pharmacokinetics of this drug. Table 1
shows the patients characteristics. Median age of the
patients was 45 years (range 22-71 years).
WHO performance status on starting the study was
0 or 1 in 26 patients each and 2 in 6 further patients.
Fourteen patients were female, eighteen patients were
male. The histological diagnosis was osteosarcoma in 4,
chondrosarcoma in 4, neuroblastoma in 1 and soft tissue
sarcoma in 23 patients. Of the soft tissue sarcoma
patients there were 10 with the diagnosis of leiomyosar-
coma. Stage according to AJCC was IIIB in 3 patients,
IVA in 5 patients and IVB in 24 patients. Overall 27
patients were pretreated, of whom 7 had more than 2
pretreatments.
Nineteen patients had extensive plasma and urinary
pharmacokinetics performed during the first cycle, seven
further patients during the second cycle and one patient
during the third cycle. The total number of cycles given
was 104. Our first patient received seven cycles in level 1
and later on two cycles in level 4. Another patient
received nine cycles in level 2. Only 5 of 32 patients had
no pretreatment and 23 patients had been previously
treated with the standard dose of IFO (^ 8 g/m2/cycle).
Response data
Table 1 shows the response of each individual patient.
There was 1 CR and 11 PR in 29 evaluable patients with
confirmed response, resulting in an overall response rate
of 41%. Of the 11 patients with a PR, 8 had been pre-
treated with IFO. One further patient (patient 29) had a
PR after two cycles, but refused further treatment and
PR could not be confirmed due to refusal of X-rays. He
was therefore counted as no change. Median duration
of response was eight months (range 3.0-19.4 months).
Median survival was 11 months (2 weeks - 3.1 years).
These results are listed in Table 1.
Toxicity
Dose limiting toxicity was neutropenia and thrombocy-
topenia with consequent infections (Table 2). According
to WHO-criteria fever and infection grade 1 and 2 were
found in 30%, grade 3 in 13% and grade 4 in 2% of 104
cycles. There was one toxic death of a 62-year-old
patient at dose level 2, who died during the first cycle
(day 14) due to septicemia with E. coli in therapy in-
duced agranulocytosis. At level 4 (18 g/m2 total dose)
grade 4 neutropenia was found in five of six patients
during cycle 1 and led to severe infections in two of six
patients. Furthermore at this dose level, thrombocyto-
penia grade 4 was found in four of six patients during
the first cycle. Therefore level 4 was found to be too toxic
for further continuation in this group of mainly pre-
treated patients and the recommended dose was con-
sidered to be 16 g/m2 (level 3). Independent of the dose
level, anemia grade 3 and 4 was found in 25% of the
patients. The overall rate of infections per patient was
17%. CNS-toxicity was usually mild (grade ^ 2 M.D.
Anderson score [27]) and was documented in 22% of the
Table 2. Toxicity WHO grades 3 + 4.
No. of patients treated
Leukocytes
Thrombocytes
Hemoglobin
Infections
Neurotoxicitya
Urotoxicity
Nausea/vomiting
Levels
1. cycle
1
4
3/4
0/4
1/4
0/4
0/4
0/4
0/4
2
4
3/3"
1/3"
0/3"
2/4
0/4
0/4
0/3"
3
19
18/19
5/19
4/19
4/19
0/19
0M9
0/19
4
6
5/6
4/6
2/6
2/6
0/6
0'6
0/6
2. cycle
1
4
4/4
1/4
2/4
1/4
0/4
0/4
0/4
2
3
2/2"
0/2"
0/3
0/3
0/3
0/3
0/3
3
16
13/15"
5/15"
5/15"
2/16
0/16
0/16
0/15"
4
3
3/3
1/3
1/3
1/3
0/3
0/3
0/3
All cycles
n = 104
32
90/99"
23/99"
25/100"
16/104
1/104
0/104
0/100b
Level 1: 12 g'nr'5d IFO: level 2: 14 g'nr'5d IFO: level 3: 16 g'm2'5d IFO: level 4: 18 g'nr'5d IFO.
a
 M.D. Anderson neurotoxicity scale [27].
Some cycles with missing hematological values and incomplete toxicity reports.
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patients. By using the M.D. Anderson neurotoxicity
score there was only one patient with grade 3 neuro-
toxicity which presented as progressing peripheral neuro-
pathy. In all instances neurotoxicity was fully reversible
within three days. CNS-toxicity was more frequent
during the first two cycles than thereafter. Nausea and
vomiting were frequently encountered (58% of all
cycles), but were of only moderate degree (21% WHO
grade 1, 37% WHO grade 2) because prophylactic
5-HT3-blockers and steroids were used. Mild urotoxicity
(grade 1) was seen in 36% of courses, but there was a
grade 2 urotoxicity in only one cycle. No grade 3 or 4
urotoxicity has been observed. Alopecia occurred in all
of the patients, many of whom had alopecia at pretreat-
ment due to prior chemotherapy. There was one patient
with an unexplained short episode of apnoea on day 4 of
the first cycle which was possibly due to chlorpromazine.
This patient recovered promptly.
Pharmacokinetics
Ifosfamide and its metabolites were detectable in plasma
and urine from all investigated patients during IFO
administration using the quantitative thin-layer chroma-
tography-photography densitometry technique (TLC).
Parent drug could also be measured by gas chromatog-
raphy (GC), which gave more reliable results at the high
concentrations seen during high-dose treatment. For
consistency, the values quoted for parent drug were
derived from GC analysis. During the infusion period,
the concentration of IFO in plasma rose to a peak after
the first 24 hours (Figure 2). Thereafter, plasma concen-
tration declined towards the end of the infusion so that
the day 5 value was on average 50% (range 0%-80%)
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Figure 2. Plasma concentration-time profile of ifosfamide and its
metabolites in patient 15.
less than that on day one, despite a continuous, constant
rate of administration. This was accompanied by an
average 50% increase in plasma concentration of
dechloroethylated metabolites (range 0%-300%). The
time-course of this effect varied. Some patients showed
a rapid decline in ifosfamide concentration to reach a
lower steady-state concentration on day two with no
further change. Others showed a steady decline in drug
concentration from day one to day five with no sign of
attaining a steady-state level. After the end of the in-
fusion, concentrations of IFO rapidly fell below the limit
of detection, with concentrations of metabolites persist-
ing slightly longer in some patients.
Plasma and urinary pharmacokinetics for IFO and
its metabolites at each dose level are given in Tables
3 and 4. Only the AUC for parent drug increased
linearly with dose (Figure 3). However, the AUCs of
the metabolites measured in plasma by TLC did not
Table 3 Plasma pharmacokinetics of total dose IFO over five days.
IFO dose
(gm-2)
12
14
16
18
No. of
cycles
7
8
7
5
IFO
9.7(8.3-14.2)
13.0(9.3-15.2)
16.1 (7.4-18.7)
16.3(12.8-20.2)
IPM
4.8 (0.9-5.6)
2.8(2.1-5.1)
2.0(0-5.3)
3.8(2.1-5.6)
CX
1.3(0.7-2.6)
1.3(0.2-3.6)
1.5(0.7-3.1)
2.4 (0.8-3.9)
3-DC1
5.5 (2.5-8 7)
4.2(2.8-8.3)
5.9 (2.6-6.6)
6.4(4.6-9.8)
2-DC1
2.7 (0.4-5.4)
2.4(1.6-3.5)
2.2(1.2-3.5)
4.2 (2.5-4.5)
IFOCI
(ml/min/m2)
4.77 (3 33-5.56)
4.13(3.54-5.81)
3.82 (3.29-8.27)
4.24(3.43-5.42)
Mean values and range (between parentheses) of AUC (in mMhr)of IFO and metabolites; data for each metabolite given as AUC (mMhr); total
clearance of IFO in ml/min/m2.
Table 4. Urinary pharmacokinetics of total dose IFO over five days.
IFO dose
g/m2
12
14
16
18
No. of
cycles
7
8
7
5
Recovery (% of dose)
IFO
11.5(9.6-28.2)
13.5(10.0-18.9)
12.6(9.5-17.4)
17.3(14.3-22.3)
IPM
6.3(1.1-14.0)
6.9(3.8-11.3)
4.2(1.6-4.4
5.0 (3.2-7.0)
CX
6.0(0.9-12.7)
10.7(6.5-16.5)
6.9(4.3-14.9)
7.3(4.8-12.3)
3-DC1
8.6(1.
8.8 (5.
6.1 (3.
6.2 (3.
7-10.7)
0-22.1)
1-8.5)
1-12.9)
2-DC1
4.9(1.1-6.9)
8.4(3.7-16.0)
5.4(2.2-7.2)
3.1(2.7-8.3)
K.ETO
0.1 (0-0.6)
0.2 (0-0.6)
0.0 (0-0.3)
0.3 (0.2-0.6)
Recovery of IFO and metabolites. Mean values and range (between parentheses) in mMhr.
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increase with dose, particularly that of IPM. This sup-
posedly active metabolite did not increase with increas-
ing doses of IFO (Figure 3). Likewise, the AUC of the
inactive metabolite CX did not increase with dose. Thus,
the lack of increase in IPM-AUC cannot be attributed to
an increase in inactivation by aldehyde dehydrogenase.
Similarly, the AUCs of the inactive dechloroethylated
metabolites did not increase in proportion to the dose.
The 4-keto-ifosfamide (KETO) was a minor metabolite
in all cases (recovery < 0.7% of the dose or undetectable).
The excretion of IFO unchanged in urine tended to
increase with dose, but this trend was only just signifi-
cant (P < 0.05). One subject (patient 26) excreted a
large percentage (28%) of a 12 g/m2 dose as unchanged
drug. If this subject is excluded, the correlation of excre-
tion of unchanged drug with dose is highly significant
(P < 0.01). The recovery of the active metabolite IPM as
a percentage of the dose administered decreased on
increasing the dose. This inverse relation was most sig-
nificant between the excretion of IPM at the dose level
of 14 and 16 g/m2 IFO (P = 0.008). In contrast the
recovery of CX increased up to 14 g/m2 and declined
thereafter similar to the 2-dechloroethyl metabolites
(Table 4).
The weak point of a dose-escalation study is that
individual patients are not studied at successive dose
levels. In the present study, two patients were analyzed
at different doses. Patient 1 had a partial remission after
seven cycles with 12 g/m2 and received two further
cycles in level 4 18 g/m2 when his tumor became pro-
gressive again. The pharmacokinetic results are sum-
marized in Figure 4. Values of AUC for metabolites are
unchanged or decreased at the higher dose, while the
AUC of ifosfamide increases proportionately to dose
and the percent of dose unchanged in urine is doubled.
This comparison of different dose levels in the same
patient again indicates saturation of metabolism.
Discussion
High-dose ifosfamide, defined as ^ 10 g/m2 per cycle, is
a very active single agent therapy even in patients pre-
viously treated with standard dose ifosfamide. As a
prodrug ifosfamide must be activated through the liver
cytochrome/?450 enzyme system and this metabolic step
may be saturated in high dose regimens. Our results
show that in the population studied here, there are
important dose-related alterations in IFO metabolism.
Furthermore there is a high interindividual variability.
The well documented phenomenon of enzyme induction
during treatment with IFO [22, 29-31] was confirmed
and the time course of the enzyme inductive effect also
varied. Some patients showed a rapid decline in IFO
concentrations over five days to reach a lower steady
state concentration on day 2, whereas other patients
showed no sign of a steady state level even after five
days. This indicates a substantial individual variability
in induction of IFO metabolism. These findings are in
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Figure 3 AUC of ifosfamide and isophosphoramide mustard at
different dose levels.
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Figure 4. Plasma AUCs (a) and urine recoveries (b) of ifosfamide and
metabolites at doses of 12 g/m2 and 18 g/m2 in patient 1.
agreement with results from pharmacokinetic studies of
children [32].
As regards the four dose levels studied, only the AUC
for the parent drug increased linearly with dose indicat-
ing that the pharmacokinetics of IFO itself are not dose
dependent over the dose range studied here. This has
already been shown in previous lower dose studies [32,
33]. This is reflected in a total clearance and renal
clearance similar to those reported previously [33-35].
However the AUCs of the metabolites measured in
plasma by TLC did not increase with the IFO dose,
particularly that of IPM which is thought to be the
main alkylating metabolite of IFO. The AUC of IPM
did not increase as much as that of IFO, implying that
the activation pathway of IFO was saturated already at
the dose levels studied here. In patients treated with
standard dose IFO, IPM metabolism was unchanged and
showed no tendency to decrease with increasing dose
[36]. Interestingly the AUC of the inactive metabolite
CX also does not increase with dose. This phenomenon
cannot be attributed to a decrease in inactivation by
aldehyde dehydrogenase enzyme (ALDH1) because the
AUCs of the inactive dechloroethylated metabolites do
not increase in proportion to the dose either. This implies
that the inactivation pathways of IFO metabolism may
also be saturated at the dose levels studied. Therefore the
excretion of unchanged IFO in urine tended to increase
with dose.
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The profile of excretion of IFO and metabolites in
urine provides further evidence of saturable metabolism.
The decrease in recovery of the active metabolite IPM,
of the inactive metabolite CX and the dechloroethyl
metabolites as the dose of IFO was increased is consis-
tent with saturable metabolism and may reflect product-
inhibition of the activating enzymes by IFO metabolites.
This inverse relation was most significant between the
IFO dose level of 14 and 16 g/m2. A similar phenomenon
has been reported for enzyme inhibition by products of
cyclophosphamide metabolism [37]
In patient 1 a dose dependency of IFO metabolism
could be investigated in an intraindividual comparison
of dose level 1 and 4. This young patient responded at
the 12 g/m2 level and was later retreated at 18 g/m2. The
comparison of the pharmacokinetic results confirm a
clear saturation of IFO metabolism with regard to both
the active and inactive metabolites. By further increas-
ing IFO from 12 to 18 g/m" no augmentation in active
IFO metabolites could be achieved. Excretion of un-
changed IFO at the higher dose level was double that at
the lower. Overall these results suggest that for high-
dose continuous IFO therapy 12-14 g/m2 might be the
optimal dose level. In a recent paper [14] it has been
questioned if short infusions compared to continuous
infusions of the same dose of IFO might be more active.
The hypothesis that continuous IFO could inhibit the
activation of IFO to a greater extent than after a short
infusion would have to be tested in a further study.
Toxicity was predominantly hematological (Table 2)
in this mostly intensively pretreated group of patients,
with WHO grade 3 and 4 leucopenia in > 90% of the
cycles. Since we encountered severe leucopenia at level 1
(12 g/m2/cycle) all patients received GM-CSF there-
after. This allowed further dose escalation up to 18
g/m2/cycle. At this level, leucopenia with infection was
clearly dose limiting and this dose cannot be recom-
mended in pretreated patients. Therefore we consider
16 g/m2 to be the recommended dose in such patients.
Infections, WHO grade 3 and 4, were seen in 15% of all
cycles with one toxic death. The unexpected low rate of
serious CNS toxicity might be due to administration as
a continuous infusion [16]. Nausea occurred frequently
and was usually of moderate degree with prophylactic
application of 5 HT3 blockers and steroids. No grade
3 or 4 nephro- or urotoxicity was observed. We also
analyzed mesna, cysteine and glutathione pharmaco-
kinetics in these patients [26]. Mesna was highly effective
in preventing bladder toxicity and mesna urinary excre-
tion did not change significantly with time. Interestingly
however, there was a depletion of circulating total
cysteine, glutathione and homocysteine. This marked
derangement of sulphydril and disulphide homeostasis
could modulate the efficacy and toxicity of ifosfamide/
mesna therapy.
The response rate of 41% in this mostly intensively
pretreated group of patients was remarkable with 1 CR
and 11 PRs in 29 evaluable patients. More significantly,
8 of the 11 patients with a PR had been pretreated with
standard-dose IFO, suggesting a dose response relation-
ship for IFO in the treatment of sarcoma patients.
Furthermore, a response was seen in three of ten pa-
tients with leiomyosarcoma (1 CR and 2 PR) which
usually is considered to be resistant to conventional
doses of IFO. In this small group of patients we could
not study the relationship between IFO metabolism and
response to chemotherapy. In view of the heterogeneity
of the disease as well as the status of pretreatment, a
far higher number of patients would be necessary to
study this.
Based on pharmacological considerations, we con-
clude that in previously treated patients high-dose IFO
is optimal at doses of 12-14 g/m2, with an MTD of 18
g/m2. For non-pretreated patients the optimal dose for
high-dose IFO treatment has yet to be defined. The
results of our study indicate that higher doses may
produce only limited benefit due to the saturable pharma-
cokinetics of IFO and its metabolites. With the support of
peripheral stem cells, very high-dose IFO-combination
regimens with up to 24 g/m2/cycle are now used with
significant toxicities [38]. It might be that such high doses
of IFO are not contributing additional therapeutic benefit
but result in increased toxicity. Pharmacological studies
would provide useful information concerning the likely
therapeutic benefit of such high doses. In sarcoma, prior
therapy with standard-dose IFO should not exclude pa-
tients from further treatment with IFO at higher dose
levels. The response rate of high-dose IFO monochemo-
therapy is promising and should be accompanied by
pharmacological studies in order to elucidate individual
metabolism on a broader range of patients.
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